Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders

Journal of Dermatological Treatment

Volumn 20, Issue 6, 2009, Pages 328-335

  Yen Moore, Angela ^a,b,c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Arlington Center for Dermatology   (United States)

Author keywords

5 fluorouracil; Actinic keratosis; Keratoacanthoma; Psoriasis; Skin cancer; Topical therapy; Vitiligo; Warts

Indexed keywords

AMINOLEVULINIC ACID; CORTICOSTEROID; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; MICROSPHERE; PLACEBO;

ACTINIC CHEILITIS; ACTINIC KERATOSIS; APPLICATION SITE REACTION; BASAL CELL CARCINOMA; CARCINOMA IN SITU; CLINICAL TRIAL; CREAM; CRYOSURGERY; DRUG FORMULATION; DRUG MECHANISM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; KERATOACANTHOMA; LOW LEVEL LASER THERAPY; NAIL DISEASE; NAIL PSORIASIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN DISEASE; VERRUCA VULGARIS; VITILIGO;

ADMINISTRATION, CUTANEOUS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; FLUOROURACIL; HUMANS; KERATOACANTHOMA; KERATOSIS, ACTINIC; NAIL DISEASES; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES; SKIN NEOPLASMS; TREATMENT OUTCOME; VITILIGO; WARTS;

EID: 72449156634     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630902789326     Document Type: Review

References (50)

1. Goldman L. The response of skin cancer to topical therapy with 5-fluorouracil. Cancer Chemother Rep. 1963;28:49-52.
2. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330-338
3. EaglsteinWH,Weinstein GD, Frost P. Fluorouracil: Mechanism of action in human skin and actinic keratoses. I. Effect on DNA synthesis in vivo. Arch Dermatol. 1970; 101:132-139
4. Fluoroplex [package insert]. Irvine, CA: Allergan, Inc.; 2004.
5. Efudex [package insert]. Costa Mesa, CA: Valeant Pharmaceuticals North America; 2005.
6. Carac [package insert]. Bridgewater, NJ: Dermik Laboratories; 2006.
7. Klein E, Helm F, Milgrom H, Stoll HL Jr, Traenkle HL. Tumors of the skin. II. Keratoacanthoma; local effect of 5-fluorouracil. Skin (Los Angeles). 1962;1:153-156
8. Jansen GT, Dillaha CJ, HoneycuttWM. Bowenoid conditions of the skin: Treatment with topical 5-fluorouracil. South Med J. 1967;60:185-188
9. Allison JR Jr. The topical use of fluorouracil in the treatment of cancers and precancers. J S C Med Assoc. 1967;63:239-1.
10. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:(1 Pt 2)S8-S10.
11. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42:(1 Pt2)S4-S7.
12. Fuchs A, Marmur E.The kinetics of skin cancer: Progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007;33:1099-1101
13. OppelT, Korting HC. Actinic keratosis:The key event in the evolution from photoaged skin to squamous cell carcinoma. Therapy based on pathogenetic and clinical aspects. Skin Pharmacol Physiol. 2004;17:67-76.
14. Lebwohl M. Actinic keratosis: Epidemiology and progression to squamous cell carcinoma. Br J Dermatol. 2003;149:(suppl 66)31-33
15. American Academy of Dermatology, American Cancer Society, Skin Cancer Foundation. Patients urged to seek treatment for actinic keratoses, recommends the American Academy of Dermatology, the American Cancer Society, and the Skin Cancer Foundation. Cutis. 1999;63:348.
16. De Berker D, McGregor JM, Hughes BR, for the British Association of Dermatologists Therapy Guidelines and Audit Subcommitte. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-230
17. Jorizzo JL. Current and novel treatment options for actinic keratosis. J Cutan Med Surg. 2004;8:(suppl 3)13-21.
18. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg. 2005;9:209-214
19. Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: A comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157:(suppl 2)34-0.
20. MclntyreWJ, Downs MR, Bedwell SA.Treatment options for actinic keratoses. Am Fam Physician. 2007;76:667-671
21. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J. Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod. Cutis. 2003;71:365-370
22. Tanghetti E,WerschlerWP. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol. 2007;6:144-147
23. Simmonds WL. Double-blind investigation comparing a 1 %-vs-5% 5-fluorouracil topical cream in patients with multiple actinic keratoses. Cutis. 1973;12:615-617
24. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. ClinTher. 2002;24:990-1000.
25. Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70:(2 suppl)22-29
26. Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: A pharmacoeconomic evaluation. Cutis. 2002;70:(2 suppl)30-36
27. Jeffes EW, McCullough JL,Weinstein GD, Kaplan R, Glazer SD, Taylor JR. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol. 2001;45:96-104.
28. Jorizzo J,Weiss J, Furst K,VandePolC, Levy SF. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: A randomized, vehicle-controlled clinical trial. Arch Dermatol. 2004;140:813-816
29. Epstein E. Treatment of lip keratoses (actinic cheilitis) with topical fluorouracil. Arch Dermatol. 1977;113:906-908
30. Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: Efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg. 2007;33:433-0.
31. Mohs FE, Jones DL, Bloom RF. Tendency of fluorouracil to conceal deep foci of invasive basal cell carcinoma. Arch Dermatol. 1978;114:1021-1022
32. Romagosa R, Saap L, Givens M, Salvarrey A, He JL, Hsia SL, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg. 2000;26:338-340
33. Ondo AL, Mings SM, Pestak RM, Shanler SD. Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol. 2006;55:1092.
34. Sturm HM. Bowen's disease and 5-fluorouracil. J Am Acad Dermatol. 1979;1:513-522
35. Thiele JJ, Ziemer M, Fuchs S, Eisner P. Combined 5-fluorouracil and Er:YAG laser treatment in a case of recurrent giant keratoacanthoma of the lower leg. Dermatol Surg. 2004;30:(12 Pt 2)1556-1560
36. Gray RJ, Meland NB.Topical 5-fluorouracil as primary therapy for keratoacanthoma. Ann Plast Surg. 2000;44:82-85
37. Singal A, Mohanty S, Bhattacharya SN, Baruah MC, Singh N. Unusual multiple keratoacanthoma in a child successfully treated with 5-fluorouracil. J Dermatol. 1997;24:546-548
38. Ebner H, Mischer P. [The local treatment of the keratoacanthoma with 5-fluorouracil.] Hautarzt. 1975;26:585-588
39. Grupper C.Treatment of keratoacanthomas by local applications of the 5-fluorouracil (5-FU) ointment. Dermatologica. 1970;140:(suppl 1)127-132
40. Goette DK, Odom RB, Arrott JW, Diakon NC, Horn RT Jr. Treatment of keratoacanthoma with topical application of fluorouracil. Arch Dermatol. 1982;118:309-311
41. Senff H, Reinel D, Matthies C, Witts D. Topical 5-fluorouracil solution in the treatment of warts - Clinical experience and percutaneous absorption. Br J Dermatol. 1988;118:409-414
42. Salk RS, Grogan KA, ChangTJ.Topical 5% 5-fluorouracil cream in the treatment of plantar warts: A prospective, randomized, and controlled clinical study. J Drugs Dermatol. 2006;5:418-424
43. Hursthouse MW. A controlled trial on the use of topical 5-fluorouracil on viral warts. Br J Dermatol. 1975;92:93-96
44. Schmidt H, Jacobsen FK. [Double-blind randomized clinical study on treatment of warts with a fluorouracil-containing topical preparation (author's transl).] Z. Hautkr. 1981;56:41-43
45. Gibbs S, Harvey I. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2006;3:CD001781.
46. de Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25:357-362
47. Fredriksson T Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol. 1974;110:735-736
48. de Jong EM, Menke HE, van Praag MC, van de Kerkhof PC. Dystrophic psoriatic fingernails treated with 1 % 5-fluorouracil in a nail penetration-enhancing vehicle: A double-blind study. Dermatology. 1999;199:313-318
49. Sethi S, Mahajan BB, Gupta RR, Ohri A. Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo. Int J Dermatol. 2007;46:875-879
50. Tsuji T, Hamada T Topically administered fluorouracil in vitiligo. Arch Dermatol. 1983;119:722-727